The American pharmaceutical company Eli Lilly has now received market approval in Australia for its Alzheimer’s drug Kisunla (donanemab), as reported earlier by Life Science Sweden. In contrast, it was confirmed in March that Leqembi (lecanemab), developed by Sweden’s Bioarctic in collaboration with Eisai, was denied approval for a second time.
Me...
The race between new alzheimer’s drugs Kisunla and Leqembi heats up
Kisunla or Leqembi? The rivalry between Eli Lilly and Bioarctic is intensifying. Where one drug gains approval, the other falls behind. Here's a look at the markets where these competing treatments are currently available.
Vill du få åtkomst till allt?
Prova 30 dagar för 0 kr.
Inga bindningstider eller kortuppgifter krävs.
Prova nu
Köp en prenumeration
Utforska våra prenumerationslösningar och välj den som passar dina behov.
Välj din prenumeration